Synopsis: Alembic Limited reported stable FY26 operational performance supported by contribution from its pharmaceuticals API, real estate and associate businesses. However, higher expenses impacted Q4FY26 profitability during the quarter.
Diversified business stock gains attention after reporting stable operational performance across its pharmaceuticals API, real estate and investment businesses during Q4FY26. The company continued benefiting from contribution from associate companies and its real estate operations despite pressure on quarterly profitability.
Alembic Limited has a total market capitalization of Rs. 2244.27 crore, according to data on the NSE. Alembic shares were trading at Rs. 87.45 apiece on the National Stock Exchange, down by 2.66 percent; the stock has declined around 4.01 percent over the last five sessions, while it has gone down about 3.07 percent in the 30 days. Over a six-month period, the stock has given a negative return of 11.62 percent, whereas on a year-on-year basis it has decreased nearly 21.07 percent, reflecting mixed overall performance. The stock’s 52-week high was Rs. 125.54 and 52-week low was Rs. 70.46.
Alembic Limited reported consolidated audited financial results for the quarter and financial year ended March 31, 2026. The company posted revenue from operations of Rs. 60.04 crore in Q4FY26 compared to Rs. 60.27 crore in Q4FY25, reflecting a marginal decline of around 0.4 percent year-on-year. Quarter over quarter, revenue also declined from Rs. 74.34 crore reported in Q3FY26.
Total income for the quarter stood at Rs. 62.18 crore in Q4FY26 compared to Rs. 63.23 crore in the corresponding quarter last year. The company continued witnessing contribution from its real estate business and active pharmaceutical ingredients segment during the quarter.
On the profitability front, the company reported net profit after tax of Rs. 9.61 crore in Q4FY26 compared to Rs. 23.75 crore in Q4FY25, reflecting a decline of around 59.5 percent year-on-year. Quarter over quarter, profit also declined from Rs. 22.47 crore reported in Q3FY26. Profit before tax stood at Rs. 18.44 crore in Q4FY26 compared to Rs. 26.92 crore in Q4FY25, reflecting a decline of around 31.5 percent year-on-year.
One of the major factors impacting margins during the quarter was the increase in total expenses and employee-related costs. Total expenses increased to Rs. 43.74 crore in Q4FY26 compared to Rs. 36.32 crore in Q4FY25. Employee benefit expenses also increased to Rs. 11.74 crore compared to Rs. 6.50 crore in the corresponding quarter last year.
For the full financial year FY26, Alembic reported revenue from operations of Rs. 239.99 crore compared to Rs. 221.89 crore in FY25, reflecting growth of around 8.2 percent year-on-year. Net profit after tax and share of associates’ profit increased to Rs. 317.38 crore in FY26 compared to Rs. 310.68 crore in FY25.
Profit before tax for FY26 stood at Rs. 148.76 crore compared to Rs. 155.50 crore in FY25. Earnings per share (EPS) for FY26 improved to Rs. 12.36 compared to Rs. 12.10 reported in the previous financial year.
Alembic Limited operates across pharmaceutical APIs, real estate and power assets businesses. The company also holds strategic stakes in Alembic Pharmaceuticals and Paushak Limited, contributing significantly to its investment and associate income.
India’s pharmaceutical and real estate sectors continue benefiting from rising healthcare demand, urban development and domestic manufacturing growth. However, profitability remains sensitive to raw material costs, regulatory changes and demand conditions across sectors.
Overall, Alembic reported stable FY26 operational performance despite pressure on quarterly profitability. Going forward, growth in the real estate business, contribution from associate companies, API demand and margin management will remain key factors influencing the company’s future performance.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Alembic Ltd Shares Down 3% as Q4 profit declines 59% YoY appeared first on Trade Brains.